Ace the 2025 MSRA Challenge – Your Multi-Specialty Success Awaits!

The treatment regimen R-CHOP is widely recognized as a standard chemotherapy protocol for treating non-Hodgkin's lymphoma, particularly for diffuse large B-cell lymphoma, which is one of the most common types. R-CHOP consists of a combination of several medications: Rituximab (R), Cyclophosphamide (C), Doxorubicin (H), Vincristine (O), and Prednisone (P). The inclusion of Rituximab, a targeted therapy that works by marking cancer cells for destruction by the immune system, significantly enhances treatment efficacy.

R-CHOP is designed to work synergistically, attacking lymphoma cells through different mechanisms while also minimizing potential harm to healthy cells. This regimen has been shown to improve overall survival rates and response rates in patients compared to chemotherapy regimens that do not include Rituximab.

The other treatment options listed are not appropriate for treating non-Hodgkin's lymphoma. COPD treatment refers to therapies focused on chronic obstructive pulmonary disease, which is unrelated to cancer. CHOP-RT indicates a treatment combining CHOP chemotherapy with radiation therapy, but it is not the standard initial treatment for non-Hodgkin's lymphoma. R-AVD, although a relevant regimen